Wednesday, January 4, 2017

Leukemia - Table of Contents alert Volume 31 Issue 1

If you are unable to see the message below, click here to view.


Volume 31, Issue 1 (January 2017)

In this issue
Original Articles
Letters to the Editor

Also new
Sign up for e-alerts Sign up for e-alerts
Recommend to your library
Web feed
Follow on Twitter

Original Articles



Ordering of mutations in acute myeloid leukemia with partial tandem duplication of MLL (MLL-PTD) OPEN

Q-Y Sun, L-W Ding, K-T Tan, W Chien, A Mayakonda, D-C Lin, X-Y Loh, J-F Xiao, M Meggendorfer, T Alpermann, M Garg, S-L Lim, V Madan, N Hattori, Y Nagata, S Miyano, A E J Yeoh, H-A Hou, Y-Y Jiang, S Takao, L-Z Liu, S-Z Tan, M Lill, M Hayashi, A Kinoshita, H M Kantarjian, S M Kornblau, S Ogawa, T Haferlach, H Yang and H P Koeffler

Leukemia 2017 31: 1-10; advance online publication, June 8, 2016; 10.1038/leu.2016.160

Abstract | Full Text

Subtype-specific patterns of molecular mutations in acute myeloid leukemia

D Rose, T Haferlach, S Schnittger, K Perglerová, W Kern and C Haferlach

Leukemia 2017 31: 11-17; advance online publication, June 10, 2016; 10.1038/leu.2016.163

Abstract | Full Text

Characterization of children with FLT3-ITD acute myeloid leukemia: a report from the AIEOP AML-2002 study group

E Manara, G Basso, M Zampini, B Buldini, C Tregnago, R Rondelli, R Masetti, V Bisio, M Frison, K Polato, G Cazzaniga, G Menna, F Fagioli, P Merli, A Biondi, A Pession, F Locatelli and M Pigazzi

Leukemia 2017 31: 18-25; advance online publication, June 28, 2016; 10.1038/leu.2016.177

Abstract | Full Text

Comparative value of post-remission treatment in cytogenetically normal AML subclassified by NPM1 and FLT3-ITD allelic ratio

J Versluis, F E M in ‘t Hout, R Devillier, W L J van Putten, M G Manz, M -C Vekemans, M -C Legdeur, J R Passweg, J Maertens, J Kuball, B J Biemond, P J M Valk, B A van der Reijden, G Meloni, H C Schouten, E Vellenga, T Pabst, R Willemze, B Löwenberg, G Ossenkoppele, F Baron, G Huls and J J Cornelissen

Leukemia 2017 31: 26-33; advance online publication, June 24, 2016; 10.1038/leu.2016.183

Abstract | Full Text

Maintenance therapy with decitabine in younger adults with acute myeloid leukemia in first remission: a phase 2 Cancer and Leukemia Group B Study (CALGB 10503)

W Blum, B L Sanford, R Klisovic, D J DeAngelo, G Uy, B L Powell, W Stock, M R Baer, J E Kolitz, E S Wang, E Hoke, K Mrózek, J Kohlschmidt, C D Bloomfield, S Geyer, G Marcucci, R M Stone, R A Larson and for the Alliance for Clinical Trials in Oncology

Leukemia 2017 31: 34-39; advance online publication, September 13, 2016; 10.1038/leu.2016.252

Abstract | Full Text


Systematic chemical and molecular profiling of MLL-rearranged infant acute lymphoblastic leukemia reveals efficacy of romidepsin OPEN

M N Cruickshank, J Ford, L C Cheung, J Heng, S Singh, J Wells, T W Failes, G M Arndt, N Smithers, R K Prinjha, D Anderson, K W Carter, A M Gout, T Lassmann, J O'Reilly, C H Cole, R S Kotecha and U R Kees

Leukemia 2017 31: 40-50; advance online publication, June 13, 2016; 10.1038/leu.2016.165

Abstract | Full Text

Idelalisib sensitivity and mechanisms of disease progression in relapsed TCF3-PBX1 acute lymphoblastic leukemia OPEN

S Eldfors, H Kuusanmäki, M Kontro, M M Majumder, A Parsons, H Edgren, T Pemovska, O Kallioniemi, K Wennerberg, N Gökbuget, T Burmeister, K Porkka and C A Heckman

Leukemia 2017 31: 51-57; advance online publication, July 27, 2016; 10.1038/leu.2016.202

Abstract | Full Text

Pegylated-asparaginase during induction therapy for adult acute lymphoblastic leukaemia: toxicity data from the UKALL14 trial OPEN

B Patel, A A Kirkwood, A Dey, D I Marks, A K McMillan, T F Menne, L Micklewright, P Patrick, S Purnell, C J Rowntree, P Smith and A K Fielding

Leukemia 2017 31: 58-64; advance online publication, August 2, 2016; 10.1038/leu.2016.219

Abstract | Full Text


Effect of tyrosine kinase inhibitors on stemness in normal and chronic myeloid leukemia cells

L Charaf, F-X Mahon, I Lamrissi-Garcia, I Moranvillier, F Beliveau, B Cardinaud, S Dabernat, H de Verneuil, F Moreau-Gaudry and A Bedel

Leukemia 2017 31: 65-74; advance online publication, May 25, 2016; 10.1038/leu.2016.154

Abstract | Full Text

The clinical significance of ABCB1 overexpression in predicting outcome of CML patients undergoing first-line imatinib treatment

L N Eadie, P Dang, V A Saunders, D T Yeung, M P Osborn, A P Grigg, T P Hughes and D L White

Leukemia 2017 31: 75-82; advance online publication, June 24, 2016; 10.1038/leu.2016.179

Abstract | Full Text


Combined copy number and mutation analysis identifies oncogenic pathways associated with transformation of follicular lymphoma

A Bouska, W Zhang, Q Gong, J Iqbal, A Scuto, J Vose, M Ludvigsen, K Fu, D D Weisenburger, T C Greiner, R D Gascoyne, A Rosenwald, G Ott, E Campo, L M Rimsza, J Delabie, E S Jaffe, R M Braziel, J M Connors, C-I Wu, L M Staudt, F D‘Amore, T W McKeithan and W C Chan

Leukemia 2017 31: 83-91; advance online publication, June 16, 2016; 10.1038/leu.2016.175

Abstract | Full Text


Immunoparesis in newly diagnosed AL amyloidosis is a marker for response and survival

E Muchtar, A Dispenzieri, S K Kumar, F K Buadi, M Q Lacy, S Zeldenrust, S R Hayman, N Leung, T V Kourelis, W Gonsalves, R Chakraborty, S Russell, D Dingli, J A Lust, Y Lin, P Kapoor, R Go, R A Kyle, S V Rajkumar and M A Gertz

Leukemia 2017 31: 92-99; advance online publication, May 23, 2016; 10.1038/leu.2016.140

Abstract | Full Text

Prognostic study for overall survival in patients with newly diagnosed POEMS syndrome

C Wang, X-F Huang, Q-Q Cai, X-X Cao, M-H Duan, H Cai, D-B Zhou and J Li

Leukemia 2017 31: 100-106; advance online publication, June 13, 2016; 10.1038/leu.2016.168

Abstract | Full Text

A randomized phase III study of carfilzomib vs low-dose corticosteroids with optional cyclophosphamide in relapsed and refractory multiple myeloma (FOCUS) OPEN

R Hájek, T Masszi, M T Petrucci, A Palumbo, L Rosiñol, A Nagler, K L Yong, A Oriol, J Minarik, L Pour, M A Dimopoulos, V Maisnar, D Rossi, H Kasparu, J Van Droogenbroeck, D B Yehuda, I Hardan, M Jenner, M Calbecka, M Dávid, J de la Rubia, J Drach, Z Gasztonyi, S Górnik, X Leleu, M Munder, M Offidani, N Zojer, K Rajangam, Y-L Chang, J F San-Miguel and H Ludwig

Leukemia 2017 31: 107-114; advance online publication, June 24, 2016; 10.1038/leu.2016.176

Abstract | Full Text

Impact of prior treatment on patients with relapsed multiple myeloma treated with carfilzomib and dexamethasone vs bortezomib and dexamethasone in the phase 3 ENDEAVOR study OPEN

P Moreau, D Joshua, W-J Chng, A Palumbo, H Goldschmidt, R Hájek, T Facon, H Ludwig, L Pour, R Niesvizky, A Oriol, L Rosiñol, A Suvorov, G Gaidano, T Pika, K Weisel, V Goranova-Marinova, H H Gillenwater, N Mohamed, S Aggarwal, S Feng and M A Dimopoulos

Leukemia 2017 31: 115-122; advance online publication, July 4, 2016; 10.1038/leu.2016.186

Abstract | Full Text

Current anti-myeloma therapies in renal manifestations of monoclonal light chain-associated Fanconi syndrome: a retrospective series of 49 patients

M Vignon, V Javaugue, M P Alexander, K El-Karoui, A Karras, D Roos-Weil, B Royer, B Asli, B Knebelmann, G Touchard, A Jaccard, B Arnulf, F Bridoux, N Leung and J P Fermand

Leukemia 2017 31: 123-129; advance online publication, July 20, 2016; 10.1038/leu.2016.195

Abstract | Full Text

Quantification of circulating clonal plasma cells via multiparametric flow cytometry identifies patients with smoldering multiple myeloma at high risk of progression

W I Gonsalves, S V Rajkumar, A Dispenzieri, D Dingli, M M Timm, W G Morice, M Q Lacy, F K Buadi, R S Go, N Leung, P Kapoor, S R Hayman, J A Lust, S J Russell, S R Zeldenrust, L Hwa, T V Kourelis, R A Kyle, M A Gertz and S K Kumar

Leukemia 2017 31: 130-135; advance online publication, July 26, 2016; 10.1038/leu.2016.205

Abstract | Full Text

Long-term event-free and overall survival after risk-adapted melphalan and SCT for systemic light chain amyloidosis OPEN

H Landau, M Smith, C Landry, J F Chou, S M Devlin, H Hassoun, C Bello, S Giralt and R L Comenzo

Leukemia 2017 31: 136-142; advance online publication, August 18, 2016; 10.1038/leu.2016.229

Abstract | Full Text


KPT-8602, a second-generation inhibitor of XPO1-mediated nuclear export, is well tolerated and highly active against AML blasts and leukemia-initiating cells OPEN

J Etchin, A Berezovskaya, A S Conway, I A Galinsky, R M Stone, E Baloglu, W Senapedis, Y Landesman, M Kauffman, S Shacham, J C Y Wang and A T Look

Leukemia 2017 31: 143-150; advance online publication, May 23, 2016; 10.1038/leu.2016.145

Abstract | Full Text

Patient-derived xenotransplants can recapitulate the genetic driver landscape of acute leukemias

K Wang, M Sanchez-Martin, X Wang, K M Knapp, R Koche, L Vu, M K Nahas, J He, M Hadler, E M Stein, M S Tallman, A L Donahue, G M Frampton, D Lipson, S Roels, P J Stephens, E M Sanford, T Brennan, G A Otto, R Yelensky, V A Miller, M G Kharas, R L Levine, A Ferrando, S A Armstrong and A V Krivtsov

Leukemia 2017 31: 151-158; advance online publication, June 13, 2016; 10.1038/leu.2016.166

Abstract | Full Text

Restoration of MYC-repressed targets mediates the negative effects of GM-CSF on RUNX1-ETO leukemogenicity

S Weng, S Matsuura, C T Mowery, S A Stoner, K Lam, D Ran, A G Davis, M-C Lo and D-E Zhang

Leukemia 2017 31: 159-169; advance online publication, June 15, 2016; 10.1038/leu.2016.167

Abstract | Full Text

Genomic characterization of high-count MBL cases indicates that early detection of driver mutations and subclonal expansion are predictors of adverse clinical outcome

S Barrio, T D Shanafelt, J Ojha, K G Chaffee, C Secreto, K M Kortüm, S Pathangey, D L Van-Dyke, S L Slager, R Fonseca, N E Kay and E Braggio

Leukemia 2017 31: 170-176; advance online publication, July 14, 2016; 10.1038/leu.2016.172

Abstract | Full Text


Substitution scanning identifies a novel, catalytically active ibrutinib-resistant BTK cysteine 481 to threonine (C481T) variant OPEN

A Hamasy, Q Wang, K E M Blomberg, D K Mohammad, L Yu, M Vihinen, A Berglöf and C I E Smith

Leukemia 2017 31: 177-185; advance online publication, May 25, 2016; 10.1038/leu.2016.153

Abstract | Full Text


Enhanced CAR T-cell engineering using non-viral Sleeping Beauty transposition from minicircle vectors

R Monjezi, C Miskey, T Gogishvili, M Schleef, M Schmeer, H Einsele, Z Ivics and M Hudecek

Leukemia 2017 31: 186-194; advance online publication, June 24, 2016; 10.1038/leu.2016.180

Abstract | Full Text


Exome sequencing identifies highly recurrent somatic GATA2 and CEBPA mutations in acute erythroid leukemia

N Ping, A Sun, Y Song, Q Wang, J Yin, W Cheng, Y Xu, L Wen, H Yao, L Ma, H Qiu, C Ruan, D Wu and S Chen

Leukemia 2017 31: 195-202; advance online publication, June 15, 2016; 10.1038/leu.2016.162

Abstract | Full Text


Principal component analysis uncovers cytomegalovirus-associated NK cell activation in Ph+ leukemia patients treated with dasatinib

K-i Ishiyama, T Kitawaki, N Sugimoto, T Sozu, N Anzai, M Okada, M Nohgawa, K Hatanaka, N Arima, T Ishikawa, S Tabata, T Onaka, S Oka, Y Nakabo, R Amakawa, M Matsui, T Moriguchi, A Takaori-Kondo and N Kadowaki

Leukemia 2017 31: 203-212; advance online publication, June 14, 2016; 10.1038/leu.2016.174

Abstract | Full Text


Induction of the 5S RNP–Mdm2–p53 ribosomal stress pathway delays the initiation but fails to eradicate established murine acute myeloid leukemia

P Jaako, A Ugale, M Wahlestedt, T Velasco-Hernandez, J Cammenga, M S Lindström and D Bryder

Leukemia 2017 31: 213-221; advance online publication, June 3, 2016; 10.1038/leu.2016.159

Abstract | Full Text

c-myb hyperactivity leads to myeloid and lymphoid malignancies in zebrafish

W Liu, M Wu, Z Huang, J Lian, J Chen, T Wang, A Y H Leung, Y Liao, Z Zhang, Q Liu, K Yen, S Lin, L I Zon, Z Wen, Y Zhang and W Zhang

Leukemia 2017 31: 222-233; advance online publication, June 14, 2016; 10.1038/leu.2016.170

Abstract | Full Text

Letters to the Editor


Cathepsin G is broadly expressed in acute myeloid leukemia and is an effective immunotherapeutic target

G Alatrash, H R Garber, M Zhang, P Sukhumalchandra, Y Qiu, H Jakher, A A Perakis, L Becker, S Y Yoo, K C Dwyer, K Coombes, A H Talukder, L S St John, V Senyukov, D A Lee, A Sergeeva, H He, Q Ma, P M Armistead, J Roszik, E A Mittendorf, J J Molldrem, D Hawke, G Lizee and S M Kornblau

Leukemia 2017 31: 234-237; advance online publication, August 30, 2016; 10.1038/leu.2016.249

Full Text

NDEL1-PDGFRB fusion gene in a myeloid malignancy with eosinophilia associated with resistance to tyrosine kinase inhibitors OPEN

K Byrgazov, R Kastner, M Gorna, G Hoermann, M Koenig, C B Lucini, R Ulreich, M Benesch, V Strenger, H Lackner, W Schwinger, P Sovinz, O A Haas, M van den Heuvel-Eibrink, C M Niemeyer, O Hantschel, P Valent, G Superti-Furga, C Urban, M N Dworzak and T Lion

Leukemia 2017 31: 237-240; advance online publication, August 30, 2015; 10.1038/leu.2016.250

Full Text

A phase II randomized study of lenalidomide or lenalidomide and rituximab as maintenance therapy following standard chemotherapy for patients with high/high-intermediate risk diffuse large B-cell lymphoma

N M Reddy, J P Greer, D S Morgan, H Chen, S I Park and K L Richards

Leukemia 2017 31: 241-244; advance online publication, September 22, 2016; 10.1038/leu.2016.255

Full Text

Mutational profiling of a MonoMAC syndrome family with GATA2 deficiency

L-W Ding, T Ikezoe, K-T Tan, M Mori, A Mayakonda, W Chien, D-C Lin, Y-Y Jiang, M Lill, H Yang, Q-Y Sun and H P Koeffler

Leukemia 2017 31: 244-245; advance online publication, September 29, 2016; 10.1038/leu.2016.256

Full Text

Kinase inhibitor ibrutinib to prevent cytokine-release syndrome after anti-CD19 chimeric antigen receptor T cells for B-cell neoplasms

M Ruella, S S Kenderian, O Shestova, M Klichinsky, J J Melenhorst, M A Wasik, S F Lacey, C H June and S Gill

Leukemia 2017 31: 246-248; advance online publication, September 28, 2016; 10.1038/leu.2016.262

Full Text

The calcineurin protein phosphatase is dispensable for BCR-ABL-induced B-ALL maintenance, propagation and response to dasatinib

F Rocchetti, C Tran Quang, A L Maragno, J Nguyen, C Lasgi and J Ghysdael

Leukemia 2017 31: 248-251; advance online publication, October 3, 2016; 10.1038/leu.2016.269

Full Text

Nuclear FOXM1 drives chemoresistance in AML

I Khan, M Halasi, M F Zia, P Gann, S Gaitonde, N Mahmud and A L Gartel

Leukemia 2017 31: 251-255; advance online publication, October 3, 2016; 10.1038/leu.2016.270

Full Text

CARMA1 is a novel regulator of T-ALL disease and leukemic cell migration to the CNS OPEN

S R Oruganti, D J Torres, S Krebsbach, F Asperti-Boursin, J Winters, K Matlawska-Wasowska, S S Winter, C Halsey and J L Cannon

Leukemia 2017 31: 255-258; advance online publication, October 4, 2016; 10.1038/leu.2016.272

Full Text

Expansion of Th1-like Vγ92T cells by new-generation IMiDs, lenalidomide and pomalidomide, in combination with zoledronic acid

T Harada, H Miki, Q Cui, A Oda, R Amachi, J Teramachi, A Bat-Erdene, K Sogabe, M Iwasa, S Fujii, S Nakamura, K Kagawa, S Yoshida, I Endo, K Aihara, S Ozaki, T Matsumoto and M Abe

Leukemia 2017 31: 258-262; advance online publication, October 4, 2016; 10.1038/leu.2016.273

Full Text

Novel evidence that the mannan-binding lectin pathway of complement activation plays a pivotal role in triggering mobilization of hematopoietic stem/progenitor cells by activation of both the complement and coagulation cascades OPEN

M Adamiak, A Abdelbaset-Ismail, M Suszynska, A Abdel-Latif, J Ratajczak and M Z Ratajczak

Leukemia 2017 31: 262-265; advance online publication, October 13, 2016; 10.1038/leu.2016.278

Full Text



Overexpression of ABCB1 as prediction marker for CML: How close we are to translation into clinics?

V Némethová and F Rázga

Leukemia 2017 31: 266-267; advance online publication, October 21, 2016; 10.1038/leu.2016.266

Full Text



Principal component analysis uncovers cytomegalovirus-associated NK cell activation in Ph+ leukemia patients treated with dasatinib

K Ishiyama, T Kitawaki, N Sugimoto, T Sozu, N Anzai, M Okada, M Nohgawa, K Hatanaka, N Arima, T Ishikawa, S Tabata, T Onaka, S Oka, Y Nakabo, R Amakawa, M Matsui, T Moriguchi, A Takaori-Kondo and N Kadowaki

Leukemia 2017 31: 268; 10.1038/leu.2016.188

Full Text

nature events
Natureevents is a fully searchable, multi-disciplinary database designed to maximise exposure for events organisers. The contents of the Natureevents Directory are now live. The digital version is available here.

Find the latest scientific conferences, courses, meetings and symposia on For event advertising opportunities across the Nature Publishing Group portfolio please contact
More Nature Events

Please note that you need to be a subscriber or site-licence holder to enjoy full-text access to Leukemia. In order to do so, please purchase a subscription.

You have been sent this Table of Contents Alert because you have opted in to receive it. You can change or discontinue your e-mail alerts at any time, by modifying your preferences on your account at: (You will need to log in to be recognised as a registrant).

For further technical assistance, please contact our registration department.

For print subscription enquiries, please contact our subscription department.

For other enquiries, please contact our customer feedback department.

Nature Publishing Group |One New York Plaza, Suite 4500 | New York | NY 10004-1562 | USA

Nature Publishing Group's worldwide offices:
London - Paris - Munich - New Delhi - Tokyo - Melbourne
San Diego - San Francisco - Washington - New York - Boston

Macmillan Publishers Limited is a company incorporated in England and Wales under company number 785998 and whose registered office is located at The Campus, 4 Crinan Street, London, N1 9XW.

© 2017 Nature Publishing Group, a division of Macmillan Publishers Limited. All Rights Reserved.

nature publishing group

No comments: